These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 33588181)

  • 1. Corrigendum to "Structure guided development of potent piperazine-derived hydroxamic acid inhibitors targeting falcilysin" [Bioorg. Med. Chem. Lett. 32 (2021) 127683].
    Kahlon G; Lira R; Masvlov N; Pompa E; Brar N; Eagon S; Anderson MO; Andaya A; Chance JP; Fejzic H; Keniston A; Huynh N; Celis N; Vidal B; Trieu N; Rodriguez P; Mallari JP
    Bioorg Med Chem Lett; 2021 Apr; 37():127836. PubMed ID: 33588181
    [No Abstract]   [Full Text] [Related]  

  • 2. Corrigendum to "Assessing the oral bioavailability of difluorosialic acid prodrugs, potent viral neuraminidase inhibitors, using a snapshot PK screening assay" [Bioorg. Med. Chem. Lett. 25 (2015) 2505-2509].
    Arns S; Tan J; Sun S; Galey A; Zisman N; Ross F; Udechukwu J; Dercho S; Gusti V; Paquette J; Wennekes T; Webb M; Bourque E; Withers SG; Liggins R
    Bioorg Med Chem Lett; 2016 Jul; ():. PubMed ID: 27381085
    [No Abstract]   [Full Text] [Related]  

  • 3. Corrigendum to "Identification of substituted benzothiazole sulfones as potent and selective inhibitors of endothelial lipase" [Bioorg. Med. Chem. Lett. 29 (2019) 1918-1921].
    Kim SH; Johnson JA; Jiang J; Parkhurst B; Phillips M; Pi Z; Qiao JX; Tora G; Ye Chen A; Liu E; Yin X; Yang R; Zhao L; Taylor DS; Basso M; Behnia K; Onorato J; Chen XQ; Abell LM; Lu H; Locke G; Caporuscio C; Adam LP; Gordon D; Wexler RR; Finlay HJ
    Bioorg Med Chem Lett; 2019 Sep; 29(17):2525. PubMed ID: 31353296
    [No Abstract]   [Full Text] [Related]  

  • 4. Corrigendum to "Optimization of a novel piperazinone series as potent selective peripheral covalent BTK inhibitors" [Bioorg. Med. Chem. Lett. 60 (2022) 128549].
    Ma B; Metrick CM; Gu C; Hoemberger M; Bajrami B; Bame E; Huang J; Mingueneau M; Murugan P; Nevalainen M; Santoro JC; Tang H; Wang T; Hopkins BT
    Bioorg Med Chem Lett; 2022 Sep; 72():128856. PubMed ID: 35728998
    [No Abstract]   [Full Text] [Related]  

  • 5. Development of piperazine-based hydroxamic acid inhibitors against falcilysin, an essential malarial protease.
    Chance JP; Fejzic H; Hernandez O; Istvan ES; Andaya A; Maslov N; Aispuro R; Crisanto T; Nguyen H; Vidal B; Serrano W; Kuwahara B; Pugne Andanado C; Goldberg DE; Mallari JP
    Bioorg Med Chem Lett; 2018 Jun; 28(10):1846-1848. PubMed ID: 29691139
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Corrigendum to 'Design and development of a series of borocycles as selective, covalent kallikrein 5 inhibitors' [Bioorg. Med. Chem. Lett. 29 (2019) 126675].
    Walker AL; Denis A; Bingham RP; Bouillot A; Edgar EV; Ferrie A; Holmes DS; Laroze A; Liddle J; Fouchet MH; Moquette A; Nassau P; Pearce AC; Polyakova O; Smith KJ; Thomas P; Thorpe JH; Trottet L; Wang Y; Hovnanian A
    Bioorg Med Chem Lett; 2020 Jan; 30(2):126771. PubMed ID: 31859161
    [No Abstract]   [Full Text] [Related]  

  • 7. Corrigendum to "Metabolism-based structure optimization: Discovery of a potent and orally available tyrosine kinase ALK inhibitor bearing the tetracyclic benzo[b]carbazolone core" [Bioorg. Med. Chem. Lett. 26 (2016) 5399-5402].
    Han M; Wang C; Ji Y; Song Z; Xing L; Su Y; Wang X; Zhang A; Ai J; Geng M
    Bioorg Med Chem Lett; 2020 Feb; 30(4):126931. PubMed ID: 31902709
    [No Abstract]   [Full Text] [Related]  

  • 8. Corrigendum to "Synthesis and biological evaluation of novel benzamide derivatives as potent smoothened antagonists" [Bioorg. Med. Chem. Lett. 24/5 (2014) 1426-1431].
    Wu TM; Wang DC; Xiang P; Zhang JN; Sang YX; Lin HJ; Chen J; Xie G; Song H; Zhao YL; Xie YM
    Bioorg Med Chem Lett; 2016 Sep; 26(18):4558. PubMed ID: 27542309
    [No Abstract]   [Full Text] [Related]  

  • 9. Corrigendum to "Strategies for the development of highly selective cytochrome P450 inhibitors: Several CYP targets in current research" [Bioorg. Med. Chem. Lett. 29 (2019) 2016-2024].
    Zhao L; Sun N; Tian L; Zhao S; Sun B; Sun Y; Zhao D
    Bioorg Med Chem Lett; 2021 Aug; 45():128140. PubMed ID: 34052643
    [No Abstract]   [Full Text] [Related]  

  • 10. Corrigendum to "Investigation of biaryl heterocycles as inhibitors of Wee1 kinase" [Bioorg. Med. Chem. Lett. 29 (2019) 1481-1486].
    Mastracchio A; Lai C; Torrent M; Bromberg K; Buchanan FG; Ferguson D; Bontcheva V; Johnson EF; Lasko L; Maag D; Shoemaker AR; Penning TD
    Bioorg Med Chem Lett; 2020 Feb; 30(4):126895. PubMed ID: 31926787
    [No Abstract]   [Full Text] [Related]  

  • 11. Corrigendum to "Design of selective PI3Kδ inhibitors using an iterative scaffold-hopping workflow" [Bioorg. Med. Chem. Lett. 29 (2019) 2575-2580].
    Fradera X; Methot JL; Achab A; Christopher M; Altman MD; Zhou H; McGowan MA; Kattar SD; Wilson K; Garcia Y; Augustin MA; Lesburg CA; Shah S; Goldenblatt P; Katz JD
    Bioorg Med Chem Lett; 2020 Aug; 30(16):127363. PubMed ID: 32591133
    [No Abstract]   [Full Text] [Related]  

  • 12. Corrigendum to "Investigation of the structure activity relationship of flufenamic acid derivatives at the human TRESK channel K2P18.1" [Bioorg. Med. Chem. Lett. 26 (2016) 4919-4924].
    Monteillier A; Loucif A; Omoto K; Stevens EB; Lainez S; Saintot PP; Cao L; Pryde DC
    Bioorg Med Chem Lett; 2017 May; 27(9):2082. PubMed ID: 28320618
    [No Abstract]   [Full Text] [Related]  

  • 13. Corrigendum to "Discovery and lead optimisation of a potent, selective and orally bioavailable RARβ agonist for the potential treatment of nerve injury" [Bioorg. Med. Chem. Lett. 29(8) (2019) 995-1000].
    Goncalves MB; Clarke E; Jarvis CI; Kalindjian SB; Pitcher T; Grist J; Hobbs C; Carlstedt T; Jack J; Brown JT; Mills M; Mumford P; Borthwick AD; Corcoran JPT
    Bioorg Med Chem Lett; 2019 Aug; 29(16):2440-2441. PubMed ID: 31208764
    [No Abstract]   [Full Text] [Related]  

  • 14. Corrigendum to 'Easy and rapid preparation of benzoylhydrazides and their diazene derivatives as inhibitors of 15-lipoxygenase' [Bioorg. Med. Chem. Lett. 27 (2017) 1649-1653].
    Tirapegui C; Acevedo-Fuentes W; Dahech P; Torrent C; Barrias P; Rojas-Poblete M; Mascayano C
    Bioorg Med Chem Lett; 2017 Sep; 27(17):4218. PubMed ID: 28780158
    [No Abstract]   [Full Text] [Related]  

  • 15. Corrigendum to "Biochemical, cellular and structural characterization of novel and selective ERK3 inhibitors" [Bioorg. Med. Chem. Lett. 30 (2020) 127551].
    Grädler U; Busch M; Leuthner B; Raba M; Burgdorf L; Lehmann M; Linde N; Esdar C
    Bioorg Med Chem Lett; 2021 Oct; 49():128262. PubMed ID: 34352662
    [No Abstract]   [Full Text] [Related]  

  • 16. Corrigendum to "Design, synthesis and biological evaluation of macrocyclic derivatives as TRK inhibitors" [Bioorg. Med. Chem. Lett. 53 (2021) 128409].
    Li P; Cai S; Zhao T; Xu L; Guan D; Li J; Zhou J; Zhang H
    Bioorg Med Chem Lett; 2022 Jan; 56():128502. PubMed ID: 34906405
    [No Abstract]   [Full Text] [Related]  

  • 17. Corrigendum to "Challenges in the development of an M
    Tarr JC; Wood MR; Noetzel MJ; Melancon BJ; Lamsal A; Luscombe VB; Rodriguez AL; Byers FW; Chang S; Cho HP; Engers DW; Jones CK; Niswender CM; Wood MW; Brandon NJ; Duggan ME; Jeffrey Conn P; Bridges TM; Lindsley CW
    Bioorg Med Chem Lett; 2018 Sep; 28(17):3014. PubMed ID: 30076050
    [No Abstract]   [Full Text] [Related]  

  • 18. Corrigendum to "The 2',4'-dihydroxychalcone could be explored to develop new inhibitors against the glycerol-3-phosphate dehydrogenase from Leishmania species" [Bioorg. Med. Chem. Lett. 25 (2015) 3564-3568].
    Passalacqua TG; Torres FAE; Nogueira CT; de Almeida L; Del Cistia ML; Dos Santos MB; Dutra LA; da Silva Bolzani V; Regasini LO; Graminha MAS; Marchetto R; Zottis A
    Bioorg Med Chem Lett; 2017 May; 27(9):2080. PubMed ID: 28363747
    [No Abstract]   [Full Text] [Related]  

  • 19. Corrigendum to "Identification of 2-substituted pyrrolo[1,2-b]pyridazine derivatives as new PARP-1 inhibitors" [Bioorg. Med. Chem. Lett. 31 (2021) 127710].
    Xiang HY; Chen JY; Huan XJ; Chen Y; Gao ZB; Ding J; Miao ZH; Yang CH
    Bioorg Med Chem Lett; 2022 Jan; 56():128501. PubMed ID: 34911648
    [No Abstract]   [Full Text] [Related]  

  • 20. Corrigendum to "Discovery of substituted 6-pheny-3H-pyridazin-3-one derivatives as novel c-Met kinase inhibitors" [Bioorg. Med. Chem. Lett. 24 (2014) 5093-5097].
    Kang ST; Kim EY; Achary R; Jung H; Park CH; Yun CS; Hwang JY; Choi SU; Chae C; Lee CO; Kim HR; Ha JD; Ryu D; Cho SY
    Bioorg Med Chem Lett; 2017 Jul; 27(14):3205. PubMed ID: 28551102
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.